Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15662770 | 0.91 | FGFR3 (0.49) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL15662902 | 0.90 | FGFR1 (0.41) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL15661893 | 0.90 | LTA4H (0.43) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL15661892 | 0.89 | TLR7 (0.52) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL15662779 | 0.88 | FGFR3 (0.40) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL15662900 | 0.87 | LTA4H (0.49) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL15662536 | 0.86 | KDR (0.47) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL15662774 | 0.86 | KDR (0.40) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL15661232 | 0.86 | MEN1 (0.52) | LTA4HHRH3HRH2HRH1MEN1 | |
| SCHEMBL15661418 | 0.86 | LTA4H (0.41) | FGFR3KDRFGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | claimed |
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-9643979-B2 | Inhibitors of DNA gyrase for the treatment of bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| WO-2014057415-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PVT LTD (IN) | 2014-04-17 | — | — | WO | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | FGFR3 1875/4885KDR 4865/4885FGFR1 2858/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | FGFR3 1971/4885KDR 4862/4885FGFR1 2650/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | FGFR3 1971/4885KDR 4862/4885FGFR1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.